

Global Axillary Hyperhidrosis Drug Pipeline Trends 2019: Discovery, Pre-clinical, Clinical, In Approval Therapeutics, Companies and Markets

https://marketpublishers.com/r/G71E1681BB9EN.html

Date: August 2019

Pages: 45

Price: US\$ 1,799.00 (Single User License)

ID: G71E1681BB9EN

Abstracts

High levels of pipeline activity are being observed in Axillary Hyperhidrosis treatment during 2019. Clinical development activities are being undertaken by more than 5 companies including Allergan Plc, Brickell Biotech Inc, Dermira Inc, GlaxoSmithKline Plc, TheraVida Inc and others.

A Significant contribution to the Axillary Hyperhidrosis pipeline is being observed from emerging companies opting for new approaches to clinical development strategy. The early stage and late-stage Axillary Hyperhidrosis pipeline included 5 compounds, driven by increasing number of targeted therapies. Progress is being made in accelerating compounds into advanced stages. However, fluctuating trends are being observed in average duration across three phases.

Increased understanding of underlying causes of Axillary Hyperhidrosis condition and increased access to investments is encouraging growth of Axillary Hyperhidrosis drug pipeline. However, despite high levels of pipeline activity, increasing clinical trial costs and decreasing drug approval rates is requiring companies to focus more on understanding clinical development pipeline compounds.

The research study is structured to provide clear and actionable insights into Axillary Hyperhidrosis drug pipeline for companies to optimize spending levels by understanding competition, their pipeline products and prospect of further advances over the next few years.

The report addresses the discovery, research and pre-clinical stage active Axillary Hyperhidrosis therapeutic candidates. Further, drugs in clinical stage including phase 1,



phase 2, phase 3 and pre-registration phases are also analyzed.

The current report examines the current Axillary Hyperhidrosis pipeline along with current development status, regulatory progress, mechanism of action, route of administration, collaborating companies, sponsors, molecule type, and research/discovery details.

In addition to drug overview, recent developments, the report also provides mechanism of action, Pre-clinical trial details and Clinical trial details for each of the drug candidates of Axillary Hyperhidrosis. Further, orphan drug status, fast track designation, grants awarded and other special status for Axillary Hyperhidrosis pipeline compounds are also included.

This study was produced independently by VPAResearch from our proprietary databases, primarily to assist users to develop in-depth understanding of 2019 Axillary Hyperhidrosis pipeline and formulate effective research and development strategies.

RESEARCH METHODOLOGY

Our integrated data reports are built through robust research methodology to ensure our users can build on the insights and data accuracy for their expansion plans. Both primary and secondary research methods are used with stringent quality checks at each stage to evaluate trends, analysis and forecasts.

Scope of the Research

Axillary Hyperhidrosis Pipeline candidates-

Pre-clinical Phase: Discovery, research, pre-clinical

Early Phase: Phase 1 and Phase 2 Axillary Hyperhidrosis drugs

Late phase: Phase 3 and in-approval Axillary Hyperhidrosis drugs

Companies involved in the Pipeline-

Company overview

Snapshot



Axillary Hyperhidrosis therapeutic treatment activities

Details for each Ax	illary Hype	erhidrosis di	rug candidate-
---------------------	-------------	---------------	----------------

Details for each Axillary Hyperhidrosis drug candidate-		
Snapshot		
Drug Name		
Alternative Names		
Company		
Originator		
Phase		
Molecule Type		
Orphan Drug Status		
Drug Overview		
Mechanism of Action		
Current Status		
Trial Details		
Other details		
Dre clinical trials for each drug condidate		

Pre-clinical trials for each drug candidate

Clinical trials for each drug candidate

Recent Axillary Hyperhidrosis therapeutic candidates, clinical trials, investments, grants,



partnerships, licenses, awards and other news



Contents

1 TABLE OF CONTENTS

- 1.1 List of Tables
- 1.2 List of Figures

2 EXECUTIVE SUMMARY

- 2.1 Axillary Hyperhidrosis- Disease Overview
- 2.2 Axillary Hyperhidrosis- Pipeline Snapshot
- 2.3 Axillary Hyperhidrosis- Pipeline Drugs by Phase
- 2.4 Axillary Hyperhidrosis- Pipeline Drugs by Company
- 2.5 Axillary Hyperhidrosis- Pipeline Drugs by Mechanism of Action

3 COMPANY WISE PIPELINE ANALYSIS

- 3.1 Allergan Plc Axillary Hyperhidrosis Drug Pipeline, H2-2019
- 3.2 Brickell Biotech Inc Axillary Hyperhidrosis Drug Pipeline, H2- 2019
- 3.3 Dermira Inc Axillary Hyperhidrosis Drug Pipeline, H2- 2019
- 3.4 GlaxoSmithKline Plc Axillary Hyperhidrosis Drug Pipeline, H2- 2019
- 3.5 TheraVida Inc Axillary Hyperhidrosis Drug Pipeline, H2- 2019

4 PHASE 1 PIPELINE DRUG DETAILS

- 4.1 Axillary Hyperhidrosis- Phase 1 Drug Details
- 4.2 Axillary Hyperhidrosis- Phase 1 Drug Overview
- 4.3 Axillary Hyperhidrosis- Phase 1 Mechanism of Action
- 4.4 Current Status
- 4.5 Trial Details

5 PHASE 2 PIPELINE DRUG DETAILS

- 5.1 Axillary Hyperhidrosis- Phase 2 Drug Details
- 5.2 Axillary Hyperhidrosis- Phase 2 Drug Overview
- 5.3 Axillary Hyperhidrosis- Phase 2 Mechanism of Action
- 5.4 Current Status
- 5.5 Trial Details



6 PHASE 3 PIPELINE DRUG DETAILS

- 6.1 Axillary Hyperhidrosis- Phase 3 Drug Details
- 6.2 Axillary Hyperhidrosis- Phase 3 Drug Overview
- 6.3 Axillary Hyperhidrosis- Phase 3 Drug Mechanism of Action
- 6.4 Current Status
- 6.5 Trial Details

7 PRE-CLINICAL PHASE PIPELINE DRUG DETAILS

- 7.1 Axillary Hyperhidrosis- Pre-clinical Phase Drug Details
- 7.2 Axillary Hyperhidrosis- Pre-clinical Phase Drug Overview
- 7.3 Axillary Hyperhidrosis- Pre-clinical Phase Drug Mechanism of Action
- 7.4 Current Status
- 7.5 Trial Details

8 RECENT NEWS AND DEVELOPMENTS

9 APPENDIX

- 9.1 About VPAResearch
- 9.2 Sources and Research Methodology



I would like to order

Product name: Global Axillary Hyperhidrosis Drug Pipeline Trends 2019: Discovery, Pre-clinical, Clinical,

In Approval Therapeutics, Companies and Markets

Product link: https://marketpublishers.com/r/G71E1681BB9EN.html

Price: US\$ 1,799.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

First name:

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/G71E1681BB9EN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

Last name:	
Email:	
Company:	
Address:	
City:	
Zip code:	
Country:	
Tel:	
Fax:	
Your message:	
	**All fields are required
	Custumer signature

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

